GH Research (NASDAQ:GHRS) Now Covered by Guggenheim

Guggenheim initiated coverage on shares of GH Research (NASDAQ:GHRS) in a research note issued to investors on Thursday, Marketbeat reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

A number of other research analysts have also commented on the stock. Stifel Nicolaus upped their price target on shares of GH Research from $18.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Monday, January 27th. Cantor Fitzgerald began coverage on shares of GH Research in a research note on Thursday, February 13th. They issued an “overweight” rating and a $14.00 price target on the stock. Royal Bank of Canada began coverage on shares of GH Research in a research note on Friday, March 7th. They issued an “outperform” rating and a $31.00 price target on the stock. Finally, Canaccord Genuity Group decreased their price target on shares of GH Research from $31.00 to $28.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, GH Research presently has a consensus rating of “Buy” and a consensus price target of $30.86.

GH Research Stock Performance

Shares of GHRS stock opened at $11.00 on Thursday. The firm’s 50-day moving average is $11.13 and its 200-day moving average is $9.18. The stock has a market cap of $572.31 million, a price-to-earnings ratio of -13.92 and a beta of 0.94. GH Research has a 52-week low of $6.00 and a 52-week high of $20.50.

GH Research (NASDAQ:GHRS) last issued its earnings results on Thursday, February 27th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. Sell-side analysts predict that GH Research will post -0.8 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. grew its position in shares of GH Research by 1.3% during the 3rd quarter. RA Capital Management L.P. now owns 6,686,689 shares of the company’s stock worth $44,734,000 after purchasing an additional 85,000 shares in the last quarter. Lynx1 Capital Management LP boosted its position in shares of GH Research by 15.8% during the 4th quarter. Lynx1 Capital Management LP now owns 4,858,994 shares of the company’s stock worth $34,013,000 after acquiring an additional 663,100 shares in the last quarter. Diadema Partners LP acquired a new stake in shares of GH Research during the 4th quarter worth approximately $711,000. Woodline Partners LP boosted its position in shares of GH Research by 112.0% during the 4th quarter. Woodline Partners LP now owns 78,949 shares of the company’s stock worth $553,000 after acquiring an additional 41,711 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of GH Research by 4.5% during the 4th quarter. Geode Capital Management LLC now owns 72,513 shares of the company’s stock worth $508,000 after acquiring an additional 3,092 shares in the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).